Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer
Author:
Funder
National Natural Science Foundation of China
Shandong Provincial Key Research and Development Program
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-020-05851-8.pdf
Reference24 articles.
1. Gianni L, Pienkowski T, Imh H et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER-2-positive breast cancer (NeoSphere): a randomized multicenter, open-label, phase 2 trial. Lancet Oncol 13(1):25–32
2. Mamtani A, Andrea V, Tari A et al (2016) How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study. Ann Surg Oncol 23(11):3467–3474
3. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460–469
4. Bines J, Earl H, Buzaid AC et al (2014) Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: Does the sequence matter? Ann Oncol 25:1079–1085
5. Grasishar WJ, Andrson BO, Balassanian R et al (2018) Breast cancer, Version 2. J Natl Compr Canc Netw 13(4):448
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Optimal management of breast cancer with physical exam negative/radiological abnormal axilla;Scientific Reports;2024-09-03
2. 3D-printed degradable paclitaxel/polylactic acid scaffolds for the treatment of breast cancer;2024-06-17
3. Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial;Journal of the National Cancer Center;2024-06
4. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis;Systematic Reviews;2024-04-04
5. Docetaxel-loaded nanoformulations delivery for breast cancer management: Challenges, recent advances, and future perspectives;Journal of Drug Delivery Science and Technology;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3